Celgene chips in $20M to extend Agios cancer deal

Agios ($AGIO) is banking a $20 million payment from Celgene ($CELG) for a deal to extend their collaboration on cancer metabolism--originally struck in 2010--by another year. Celgene now has an exclusive option on any of the drug candidates they discover through April 2015. Agios initially scored a $130 million upfront for the pact. "We are pleased that while AG-221 and AG-120 are advancing into clinical development, significant progress is also being made on new targets in cancer metabolism," noted Tom Daniel, the research chief at Celgene, which has been executing a long lineup of deals in recent years. Release

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.